These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 24632931)

  • 1. Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy.
    Gubbins PO; Klepser ME; Dering-Anderson AM; Bauer KA; Darin KM; Klepser S; Matthias KR; Scarsi K
    J Am Pharm Assoc (2003); 2014; 54(2):163-71. PubMed ID: 24632931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States.
    Weber NC; Klepser ME; Akers JM; Klepser DG; Adams AJ
    Expert Rev Mol Diagn; 2016; 16(2):253-64. PubMed ID: 26560318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for Pharmacy-Public Health Collaborations Using Pharmacy-Based Point-of-Care Testing Services for Infectious Diseases.
    Gubbins PO; Klepser ME; Adams AJ; Jacobs DM; Percival KM; Tallman GB
    J Public Health Manag Pract; 2017; 23(6):593-600. PubMed ID: 27997479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-Care Testing in Community Pharmacies: Keys to Success From Pennsylvania Pharmacists.
    Steltenpohl EA; Barry BK; Coley KC; McGivney MS; Olenak JL; Berenbrok LA
    J Pharm Pract; 2018 Dec; 31(6):629-635. PubMed ID: 29034781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project.
    Dong BJ; Lopez M; Cocohoba J
    J Am Pharm Assoc (2003); 2017; 57(4):510-515.e2. PubMed ID: 28602784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacy-based CLIA-waived testing in the United States: Trends, impact, and the road ahead.
    Zalupski B; Elroumi Z; Klepser DG; Klepser NS; Adams AJ; Klepser ME
    Res Social Adm Pharm; 2024 Jun; 20(6):146-151. PubMed ID: 38519341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community pharmacy-based point-of-care testing: A case study of pharmacist-physician collaborative working relationships.
    Bacci JL; Klepser D; Tilley H; Smith JK; Klepser ME
    Res Social Adm Pharm; 2018 Jan; 14(1):112-115. PubMed ID: 28082033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular point-of-care testing in the community pharmacy setting: current status and future prospects.
    Klepser M; Koski RR
    Expert Rev Mol Diagn; 2022 Oct; ():1-14. PubMed ID: 36269237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.S. community pharmacies as CLIA-waived facilities: Prevalence, dispersion, and impact on patient access to testing.
    Klepser ME; Adams AJ; Srnis P; Mazzucco M; Klepser D
    Res Social Adm Pharm; 2016; 12(4):614-21. PubMed ID: 26508268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-reported clinical pharmacy service provision in Austria: an analysis of both the community and hospital pharmacy sector-a national study.
    Deibl S; Mueller D; Kirchdorfer K; Stemer G; Hoppel M; Weidmann AE
    Int J Clin Pharm; 2020 Aug; 42(4):1050-1060. PubMed ID: 32494989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supporting patients with mental illness: Deconstructing barriers to community pharmacist access.
    Calogero S; Caley CF
    J Am Pharm Assoc (2003); 2017; 57(2):248-255. PubMed ID: 28153705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics in a community pharmacy: ACT now.
    Padgett L; O'Connor S; Roederer M; McLeod H; Ferreri S
    J Am Pharm Assoc (2003); 2011; 51(2):189-93. PubMed ID: 21382809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point-of-care screenings at the University of Minnesota: mechanism for civic engagement.
    Palombi LC; Bastianelli K; Stratton T
    J Am Pharm Assoc (2003); 2014; 54(1):56-62. PubMed ID: 24407741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' perspectives on HIV testing in community pharmacies.
    Ryder PT; Meyerson BE; Coy KC; von Hippel CD
    J Am Pharm Assoc (2003); 2013; 53(6):595-600. PubMed ID: 24091415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to facilitate the implementation of collaborative practice agreements in chain community pharmacies.
    Bacci JL; Coley KC; McGrath K; Abraham O; Adams AJ; McGivney MS
    J Am Pharm Assoc (2003); 2016; 56(3):257-265.e2. PubMed ID: 27053276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient attitudes regarding pharmacist-administered memory screening in community pharmacies.
    Breslow RM
    J Am Pharm Assoc (2003); 2013; 53(6):648-51. PubMed ID: 24185433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled study of practice facilitation to improve the provision of medication management services in Alberta community pharmacies.
    Houle SK; Charrois TL; Faruquee CF; Tsuyuki RT; Rosenthal MM
    Res Social Adm Pharm; 2017; 13(2):339-348. PubMed ID: 27017157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ability of community pharmacists to independently perform CLIA-waived testing - A multistate legal review.
    Doucette J; Lavino J
    Explor Res Clin Soc Pharm; 2021 Jun; 2():100024. PubMed ID: 35481127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceived barriers to provision of medication therapy management services (MTMS) and the likelihood of a pharmacist to work in a pharmacy that provides MTMS.
    Blake KB; Madhavan SS
    Ann Pharmacother; 2010 Mar; 44(3):424-31. PubMed ID: 20179254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing roles of pharmacists in community pharmacies: perception of reality in India.
    Basak SC; van Mil JW; Sathyanarayana D
    Pharm World Sci; 2009 Dec; 31(6):612-8. PubMed ID: 19554470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.